HIGHLIGHTS
- who: MPS and colleagues from the Institute of Congenital Metabolic Diseases, Paracelsus Medical University, Salzburg, Austria, European Reference Network for have published the article: The In fl ammation in the Cytopathology of Patients With Mucopolysaccharidoses- Immunomodulatory Drugs as an Approach to Therapy, in the Journal: (JOURNAL)
- what: The authors focus on market-approved drugs, which may be repurposed to be used in MPS patients. Ausseil et_al have demonstrated that in MPSIIIB mice deficient TLR4, neurodegeneration can occur autonomously of microglial activation by HS, assuming that inflammation via this pathway is not the main reason for . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.